Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 7.23B 6.48B 5.96B 5.4B 10.09B 687B 10.28B 71.05B 28.52B 361B 27.14B 26.57B 1,139B P/E 2026 *
-12.2x
P/E 2027 * -22.3x
Enterprise Value 7.13B 6.39B 5.87B 5.32B 9.95B 677B 10.13B 70.04B 28.12B 356B 26.76B 26.19B 1,123B EV / Sales 2026 *
7.73x
EV / Sales 2027 * 5.37x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.96%
1 week+1.37%
Current month-2.53%
1 month-2.53%
3 months-18.32%
6 months-41.79%
Current year-44.99%
1 week 42.76
Extreme 42.76
45.84
1 month 42.08
Extreme 42.08
45.84
Current year 42.08
Extreme 42.08
86.74
1 year 42.08
Extreme 42.08
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Others

Chief Technology Officer

110 0.0001%
31/8/26 Others

Executive/Senior Manager

58 0.0000%
31/8/26 Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%+1.37%-41.32%-1.09% 7.23B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.11%+6.92%+38.94%+185.58% 40.16B
Weighted average by Cap. +0.14%+5.37%+46.88%+182.76%

Financials

2026 *2027 *
Net sales 922M 826M 760M 688M 1.29B 87.58B 1.31B 9.06B 3.64B 46.07B 3.46B 3.39B 145B 1.36B 1.22B 1.12B 1.02B 1.9B 129B 1.93B 13.36B 5.36B 67.92B 5.1B 5B 214B
Net income -579M -519M -477M -432M -808M -55.01B -823M -5.69B -2.28B -28.94B -2.17B -2.13B -91.26B -327M -293M -270M -244M -457M -31.08B -465M -3.22B -1.29B -16.35B -1.23B -1.2B -51.56B
Net Debt -103M -92.24M -84.84M -76.88M -144M -9.78B -146M -1.01B -406M -5.14B -387M -378M -16.22B 68.31M 61.18M 56.27M 50.99M 95.31M 6.49B 97.09M 671M 269M 3.41B 256M 251M 10.76B
Projected Income Statement - Annual - Ionis Pharmaceuticals, Inc.
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
30/10/26 USD 43.52 -1.96% 1,522,192
29/10/26 USD 44.39 -1.14% 1,833,848
28/10/26 USD 44.90 +2.14% 1,724,370
27/10/26 USD 43.96 +1.24% 2,376,841
26/10/26 USD 43.42 +1.14% 3,197,537
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Ionis Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
43.52USD
Average target price
84.13USD
Spread / Average Target
+93.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ionis Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IONS Stock